Literature DB >> 24279855

Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.

Lieke van Huis-Tanja1, Dinemarie Kweekel, Hans Gelderblom, Miriam Koopman, Kees Punt, Henk-Jan Guchelaar, Tahar van der Straaten.   

Abstract

BACKGROUND & AIM: Results from different pharmacogenetic association studies in colorectal cancer are often conflicting. Both peripheral blood and formalin-fixed, paraffin-embedded (FFPE) tissue are routinely used as DNA source. This could cause bias due to somatic alterations in tumor tissue, such as loss of heterozygosity. We therefore compared genotypes in DNA from peripheral blood and FFPE colorectal tumor samples for SNPs with putative influence on the cytotoxicity of chemotherapy. MATERIALS &
METHODS: Eleven SNPs in nine genes involved in anticancer drug metabolism or efficacy were determined in matched samples from blood and FFPE tissue of colorectal tumors by pyrosequencing and TaqMan(®) techniques. The κ-statistic was calculated to assess concordance.
RESULTS: A total of 149 paired FFPE tissue and EDTA blood DNA samples were available for comparison. Overall, 20 out of 1418 genotypes were discordant (1.4%); in ten cases, loss of heterozygosity could not be ruled out. Only GSTP1 showed significant discordance between FFPE tissue and blood genotype (κ = 0.947; 95% CI: 0.896-0.998).
CONCLUSION: FFPE tissue-derived DNA can be used as a valid proxy for germline DNA for a selection of SNPs in (retrospective) pharmacogenetic association studies in colorectal cancer. However, for future studies, genotyping of blood-derived DNA is preferred.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24279855     DOI: 10.2217/pgs.13.169

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  10 in total

1.  Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Authors:  Daniel L Hertz; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Meredith M Regan; Todd C Skaar; N Lynn Henry; Daniel F Hayes; Catherine H Van Poznak; James M Rae
Journal:  Mol Oncol       Date:  2015-07-29       Impact factor: 6.603

2.  A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Authors:  Martin D Berger; Sebastian Stintzing; Volker Heinemann; Shu Cao; Dongyun Yang; Yu Sunakawa; Satoshi Matsusaka; Yan Ning; Satoshi Okazaki; Yuji Miyamoto; Mitsukuni Suenaga; Marta Schirripa; Diana L Hanna; Shivani Soni; Alberto Puccini; Wu Zhang; Chiara Cremolini; Alfredo Falcone; Fotios Loupakis; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2017-12-05       Impact factor: 12.531

3.  Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

Authors:  Y Sunakawa; S Stintzing; S Cao; V Heinemann; C Cremolini; A Falcone; D Yang; W Zhang; Y Ning; S Stremitzer; S Matsusaka; S Yamauchi; A Parekh; S Okazaki; M D Berger; S Graver; A Mendez; S J Scherer; F Loupakis; H-J Lenz
Journal:  Ann Oncol       Date:  2015-09-28       Impact factor: 32.976

4.  AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients.

Authors:  Abolfazl Avan; Amir Avan; Tessa Y S Le Large; Andrea Mambrini; Niccola Funel; Mina Maftouh; Majid Ghayour-Mobarhan; Maurizio Cantore; Ugo Boggi; Godefridus J Peters; Paola Pacetti; Elisa Giovannetti
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

5.  Functional polymorphisms of the lncRNA H19 promoter region contribute to the cancer risk and clinical outcomes in advanced colorectal cancer.

Authors:  Wenyan Qin; Xiaodong Wang; Yilin Wang; Yalun Li; Qiuchen Chen; Xiaoyun Hu; Zhikun Wu; Pengfei Zhao; Shanqiong Li; Haishan Zhao; Weifan Yao; Jian Ding; Minjie Wei; Huizhe Wu
Journal:  Cancer Cell Int       Date:  2019-08-20       Impact factor: 5.722

6.  The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.

Authors:  Danny Houtsma; Stefanie de Groot; Renee Baak-Pablo; Elma Meershoek-Klein Kranenbarg; Caroline M Seynaeve; Cornelis J H van de Velde; Stefan Böhringer; Judith R Kroep; Henk -Jan Guchelaar; Hans Gelderblom
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

7.  Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue.

Authors:  Giorgia Marisi; Alessandro Passardi; Daniele Calistri; Wainer Zoli; Dino Amadori; Paola Ulivi
Journal:  Int J Mol Sci       Date:  2014-07-30       Impact factor: 5.923

8.  Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Authors:  Francesco Sclafani; Ian Chau; David Cunningham; Andrea Lampis; Jens Claus Hahne; Michele Ghidini; Hazel Lote; Domenico Zito; Josep Tabernero; Bengt Glimelius; Andres Cervantes; Ruwaida Begum; David Gonzalez De Castro; Sanna Hulkki Wilson; Clare Peckitt; Zakaria Eltahir; Andrew Wotherspoon; Diana Tait; Gina Brown; Jacqueline Oates; Chiara Braconi; Nicola Valeri
Journal:  Carcinogenesis       Date:  2016-07-05       Impact factor: 4.944

9.  Association of AGTR1 (A1166C) and ACE (I/D) Polymorphisms with Breast Cancer Risk in North Indian Population.

Authors:  Anukriti Singh; Nidhi Srivastava; Sonal Amit; S N Prasad; M P Misra; Bushra Ateeq
Journal:  Transl Oncol       Date:  2018-02-03       Impact factor: 4.243

10.  ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.

Authors:  Maja Guberina; Ali Sak; Christoph Pöttgen; Ingeborg Tinhofer-Keilholz; Volker Budach; Panagiotis Balermpas; Jens Von der Grün; Claus Michael Rödel; Eleni Gkika; Anca-Ligia Grosu; Amir Abdollahi; Jürgen Debus; Claus Belka; Steffi Pigorsch; Stephani E Combs; David Mönnich; Daniel Zips; Chiara De-Colle; Stefan Welz; Annett Linge; Fabian Lohaus; Gustavo Baretton; Thomas Gauler; Michael Baumann; Mechthild Krause; Martin Schuler; Agnes Bankfalvi; Benedikt Höing; Stephan Lang; Martin Stuschke
Journal:  Pharmacogenomics J       Date:  2020-06-16       Impact factor: 3.550

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.